Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELINDA: Tisagenlecleucel vs standard therapy in adult relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
CTR20200561Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2020
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of tisagenlecleucel in mature B-cell lymphoma, sponsored by Novartis. Started Jun 2020; status: completed.
02
Drugs
tisagenlecleucel
03
Conditions
mature B-cell lymphoma
Beyond the preview
Go deeper on CTR20200561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200561.